In spring 2022, an inpatient Phase II Clinical Trial has been started to study safety and efficacy of

Neuro-Cells® treatment for Traumatic Spinal Cord Injury.

 

In September 2022, halfway patient inclusion was reached with no reported serious events until this point.

​

• Randomized, placebo-controlled study

• Early and late intervention cross-over design: the intervention group receives Neuro-Cells® immediately with six months follow-up. The placebo group will receive a placebo at first, but will also be treated and followed up with Neuro-Cells® after the intervention groups' primary endpoints are reached

• Will involve 16 sub-acute patients that will be included six to eight weeks after sustaining trauma to the spinal cord

• Under official approval from the Spanish ethical committee and competent authority Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS)

​

​

In collaboration with: Hospital Nacional de Parapléjicos, Toledo, Spain.